Introduction: Hypersensitivity reactions (HSRs) to colecalciferol (vitamin D) have been rarely reported and the mechanism is unknown. As an alternative treatment was not recommended for vitamin D deficiency, a desensitization protocol with colecalciferol can be performed. We found that there is no standard desensitization protocol for vitamin D. In this study, we aimed to investigate clinical features and skin test results of patients with HSRs to the vitamin D and effectiveness of the 6-step desensitization protocol in which we applied oral drops of colecalciferol.
Method: This retrospective cross-sectional study included 18 patients with a history of HSRs to oral vitamin D supplements and patients who were planned to receive oral vitamin D replacement. Before desensitization, some of the patients underwent skin tests (skin prick test and intradermal test) with colecalciferol, and the results were recorded. Skin tests were not performed in patients with a history of drug use (antihistamine, systemic steroid, omalizumab, etc.) that affected the results of skin tests. All patients were applied an one bag 6-step desensitization protocol with colecalciferol. Vitamin D3 solution was administered totally 30 drop (4000 IU)/day (1 drop:133.33 IU of 3333 IU/mL) dose of colecalciferol (Devit-3®, DEVA-Türkiye, 15 mL/50,000 IU, 1 mL = 25 drop) at 15-minutes intervals without premedication.
Results: The patient group consisted of 16 female subjects (89%); the mean age was 46 ± 12 years. When the patients were evaluated in terms of the risk of hypersensitivity reactions according to their clinical history, 5 patients had a history of anaphylaxis with vitamin D preparations (colecalciferol oral drop, n = 3; colecalciferol capsule, n = 2), and 13 patients had a history of HSRs other than anaphylaxis with isolated cutaneous reactions (pruritus, flushing, urticaria and angioedema) (n = 11, colecalciferol oral drop; n = 2, colecalciferol capsule). Skin prick test (SPT) and intradermal test (IDT) were performed on 9 patients. SPTs and IDTs were negative in all patients. Urticaria occur during desensitization in only one patient but vitamin D replacement was performed within the following 48-72 h after HSRs. All other patients tolerated 30 drop (4000 IU) and have continued to take same dose every day for the last 6 weeks with no adverse reactions.
Conclusion: Desensitization with oral vitamin D preparations has a crucial role for patients who can not receive vitamin D supplements by other ways. Vitamin D drop forms, which are better absorbed than capsule forms which contains the lowest units per/mL without the need to dilute the preparation, not contain any additives with HSRs potential such as gelatin and peanut oil are good option. Our 6-step desensitization protocol with oral drop of colecalciferol is a reliable protocol in patients with a history of vitamin D HSRs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873155 | PMC |
http://dx.doi.org/10.1016/j.waojou.2025.101029 | DOI Listing |
Clin Oral Investig
March 2025
Department of Preventive and Restorative Dentistry, Araçatuba School of Dentistry, São Paulo State University (UNESP), Araçatuba, SP, Brazil.
Objectives: This systematic review and meta-analysis (SRM) evaluated the effect of incorporating calcium-based bioactive agents in bleaching gels on dental structure preservation and whitening efficacy.
Methods: A comprehensive search was conducted across databases up to November 2024. Two independent reviewers screened and selected clinical trials and in vitro studies evaluating the effects of calcium-based bioactive agents in bleaching gels, following predefined PICO criteria.
Eur J Pediatr
March 2025
Pediatric Immunology and Allergy Department, Ankara Bilkent City Hospital, Ankara, Turkey.
The aim of the study is to elucidate demographic characteristics, risk factors, clinical presentations, causative agents, and management approaches pertaining to drug-related anaphylaxis in the paediatric population. This study is a multicenter retrospective study that included paediatric patients aged between 1 month and 18 years, who were admitted to the Pediatric Allergy and Immunology outpatient clinics of 11 participating centres with a presumptive diagnosis of drug-induced anaphylaxis, that fulfilled the standardised criteria for anaphylaxis, between January 2017 and December 2022. A total of 293 anaphylactic episodes presented among 265 patients, of which 48.
View Article and Find Full Text PDFAsia Pac Allergy
March 2025
Allergy and Clinical Immunology Unit, Coimbra Hospital and University Centre, Coimbra, Portugal.
Monoclonal antibodies have gained prominence in treating cancer and inflammatory diseases, but their increased use is linked to rising hypersensitivity reactions. Our case report focuses on a 32-year-old female with Crohn's disease treated initially with adalimumab and later with ustekinumab. Despite ustekinumab's generally safe profile, the patient developed increasingly severe mucocutaneous reactions.
View Article and Find Full Text PDFAsia Pac Allergy
March 2025
Allergy and Clinical Immunology Department, Coimbra Hospitalar and University Center, Coimbra, Portugal.
Neuromyelitis optica is a rare, inflammatory autoimmune disease of the central nervous system. Tocilizumab is a humanized monoclonal antibody, which targets the inhibition of the interleukin-6 receptor, a mediator with an important role in the pathophysiological mechanism of neuromyelitis optica. Hypersensitivity reactions to tocilizumab are rare, but similar to other biological drugs can elicit a hypersensitivity reaction.
View Article and Find Full Text PDFNeuropsychol Rehabil
March 2025
School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
Posttraumatic stress disorder (PTSD) is prevalent in individuals with acquired brain injury (ABI). This study investigated the effectiveness and applicability of Eye Movement Desensitization and Reprocessing (EMDR) for PTSD in individuals with ABI. Data were collected using a non-concurrent multiple baseline single case experimental design (SCED), with a baseline, treatment, maintenance, and 3-month follow-up phase, across four cases.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!